Időskori makuladegeneráció: ki dolgozik rajta

Intézményenként egy kártya. Szűrhetsz célpontra, országra, vagy csak az EU-13 (Horizon Europe felzárkózó) országok intézményeire.

• Minden célpont
• VEGF 19
• NRF2 0
• GLP-1 0
• PPAR 0
• AKT 0
• JNK 0
• APOE 0
• PI3K 0
• SIRT1 0
• ALK 1
• AMPK 0
• MAPK 0
• mTOR 0
• GPX4 0
• JAK 0
• NLRP3 0
• TP53 0
• ERK 0
• PCSK9 0
• STAT3 0
• STING 0
• YAP 0
• BCL-2 0
• CTNNB1 0
• CXCR4 0
• HIF-1 0
• IL-6 0
• MMP-9 1
• PDGFR 0
• SGLT2 1
• TNF 0
• IL-17 0
• MDM2 0
• MYC 0
• NOTCH3 0
• PKM2 0
• RPGR 0
• SOD1 0
• TERT 0
• TFEB 0
• TREM2 0

Az EU-13 szűrő, nem rangsor: csak szűkíti a listát.

1019 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06961370· Hoffmann-La Roche· Frissítve: 2026. nov. 4.

  “The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the protocol-defined stopping criteria.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration

  NCT05780931· VA Office of Research and Development· Frissítve: 2026. okt. 5.

  “I was instructed to stop the study, because the underlying VA grant has run out of funds.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of New Mutations in Cone Disorders

  NCT04658251· University Hospital, Lille· Frissítve: 2026. máj. 22.

  “End of COVID”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Study of the SING IMT in an Israeli Cohort

  NCT05941273· VisionCare, Inc.· Frissítve: 2026. máj. 18.

  “This decision is driven by the sponsor's strategic considerations.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

  NCT03846193· Gyroscope Therapeutics Limited· Frissítve: 2026. jan. 28.

  “The study was terminated due to the interim analysis demonstrating lack of treatment efficacy.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04566445· Gyroscope Therapeutics Limited· Frissítve: 2026. jan. 28.

  “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04437368· Gyroscope Therapeutics Limited· Frissítve: 2026. jan. 27.

  “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

  NCT05893537· Cognition Therapeutics· Frissítve: 2025. ápr. 16.

  “The trial was closed as part of a strategic business decision.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Subthreshold Laser Treatment in Intermediate Age-related Macular Degeneration With Nascent Geographic Atrophy Study

  NCT05200624· Center for Eye Research Australia· Frissítve: 2025. ápr. 15.

  “Difficulty with meeting recruitment targets”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

  NCT04764656· Novartis Pharmaceuticals· Frissítve: 2025. márc. 25.

  “The study was terminated earlier since the obtained sample was not representative of the Portuguese population, and pointed to the high fragility in evaluating the data, making it difficult to carry out a statistical study and draw valid conclusions.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  NCT07441642· Novartis Pharmaceuticals· Forrás

• A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

  NCT06847542· Hoffmann-La Roche· Forrás

• Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration

  NCT07084883· iHealthScreen Inc· Forrás

• A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Regeneron Pharmaceuticals· Forrás

• A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06635148· Janssen Research & Development, LLC· Forrás

• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

  NCT04853251· Genentech, Inc.· Forrás

• Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

  NCT06018558· Ocugen· Forrás

• Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss

  NCT07216924· University of Minnesota· Forrás

• A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

  NCT04657289· Hoffmann-La Roche· Forrás

• Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· AbbVie· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 5
• Organoids 11
• Mendelian Randomization Analysis 25
• CRISPR-Cas Systems 7
• Gene Expression Profiling 16
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 21
• Metabolomics 16
• Mass Spectrometry 11
• Flow Cytometry 8
• Immunohistochemistry 15
• Liquid Biopsy 1
• Magnetic Resonance Imaging 6
• Machine Learning 14
• Deep Learning 31
• Cohort Studies 26
• Genome-Wide Association Study 23

• Integrative Proteogenomics and Single-Cell Transcriptomics Prioritize Candidate Causal Proteins and Therapeutic Targets in Age-Related Macular Degeneration.

  Int J Mol Sci, 2026. szept.

• Cell-state-resolved transcriptomic analysis reveals macrophage-centered pyroptosis-related inflammatory programs in age-related macular degeneration.

  SLAS Technol, 2026. júl.

• Patient induced pluripotent stem cells identify specificities of a reticular pseudodrusen phenotype in age-related macular degeneration.

  Genome Med, 2026. máj.

• Integrated transcriptomic and metabolomic analyses reveal distinct energy metabolic signatures and functional properties of RPE cells under two culture conditions.

  Sci Rep, 2026. ápr.

• Mapping the Hypoxic Fitness Landscape of Retinal Pigment Epithelial Cells.

  Int J Mol Sci, 2026. márc.

• PANoptosis-Related Diagnostic Biomarkers in Non-Neovascular Age-Related Macular Degeneration: An Integrative Transcriptomic and Experimental Study.

  Genet Res (Camb), 2026. febr.

• Shared diagnostic biomarkers and diagnostic models of age-related macular degeneration and systemic lupus erythematosus.

  Int Ophthalmol, 2026. febr.

• An integrative multi-omics study reveals glutamine metabolism dysregulation connecting Alzheimer's disease and age-related macular degeneration.

  J Alzheimers Dis, 2026. jan.

• Comprehensive transcriptomic analysis reveals canonical and novel pathways modulated by nanoceria in mammalian retinal degeneration.

  Sci Rep, 2026. jan.

• Comparative transcriptomic analysis of retinal response to diverse cellular stresses reveals relative contributions of different cell death processes and signalling networks.

  Cell Death Dis, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.